ABSTRACT
The Benefit, Evidence, and STory (BEST) framework is designed to help us explore potential and strategy for access and pricing for a drug by following the following steps: perform detailed benefits analysis, assess evidence needs and build and test payer value story. The benefit pyramid is a useful tool in linking product attributes to clinical, humanistic, economic, organizational excellence and public health benefits. Most large pharmaceutical companies are focusing on a limited number of disease areas as part of their corporate strategy. Organizational excellence benefits include performance metrics, such as patient outcomes statistics (HEDIS, ACO-33 scores, other) and patient satisfaction score that can have an impact on reimbursement rates, as well as their general attractiveness to patients. Many pharmaceutical companies are still basing Phase III clinical trials decisions mainly on regulatory requirements. The role of economic data is very different between countries and payer segments.
